Skip to main content
NCBI home page
Transactions of the American Clinical and Climatological Association logoLink to Transactions of the American Clinical and Climatological Association
. 2001;112:14–26.

Farming for spare body parts: silk purse or sow's ear.

J P Atkinson 1
PMCID: PMC2194407  PMID: 11413773

Full text

PDF
14

Images in this article

16Fig. 1
on p.16
17Fig. 2
on p.17
18Fig. 3
on p.18
20Fig. 4
on p.20

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Allan J. Silk purse or sow's ear. Nat Med. 1997 Mar;3(3):275–276. doi: 10.1038/nm0397-275. [DOI] [PubMed] [Google Scholar]
  2. Alwayn I. P., Basker M., Buhler L., Cooper D. K. The problem of anti-pig antibodies in pig-to-primate xenografting: current and novel methods of depletion and/or suppression of production of anti-pig antibodies. Xenotransplantation. 1999 Aug;6(3):157–168. doi: 10.1034/j.1399-3089.1999.00030.x. [DOI] [PubMed] [Google Scholar]
  3. Bach F. H., Robson S. C., Winkler H., Ferran C., Stuhlmeier K. M., Wrighton C. J., Hancock W. W. Barriers to xenotransplantation. Nat Med. 1995 Sep;1(9):869–873. doi: 10.1038/nm0995-869. [DOI] [PubMed] [Google Scholar]
  4. Bach F. H., Winkler H., Ferran C., Hancock W. W., Robson S. C. Delayed xenograft rejection. Immunol Today. 1996 Aug;17(8):379–384. doi: 10.1016/0167-5699(96)10024-4. [DOI] [PubMed] [Google Scholar]
  5. Bach F. H. Xenotransplantation: problems and prospects. Annu Rev Med. 1998;49:301–310. doi: 10.1146/annurev.med.49.1.301. [DOI] [PubMed] [Google Scholar]
  6. Bailey L. L., Nehlsen-Cannarella S. L., Concepcion W., Jolley W. B. Baboon-to-human cardiac xenotransplantation in a neonate. JAMA. 1985 Dec 20;254(23):3321–3329. [PubMed] [Google Scholar]
  7. Birmingham K. FDA subcommittee finds no evidence of PERV transmission. Nat Med. 1999 Aug;5(8):855–855. doi: 10.1038/11275. [DOI] [PubMed] [Google Scholar]
  8. Chapman L. E., Folks T. M., Salomon D. R., Patterson A. P., Eggerman T. E., Noguchi P. D. Xenotransplantation and xenogeneic infections. N Engl J Med. 1995 Nov 30;333(22):1498–1501. doi: 10.1056/NEJM199511303332211. [DOI] [PubMed] [Google Scholar]
  9. Chen R. H., Naficy S., Logan J. S., Diamond L. E., Adams D. H. Hearts from transgenic pigs constructed with CD59/DAF genomic clones demonstrate improved survival in primates. Xenotransplantation. 1999 Aug;6(3):194–200. doi: 10.1034/j.1399-3089.1999.00017.x. [DOI] [PubMed] [Google Scholar]
  10. Costa C., Zhao L., Burton W. V., Bondioli K. R., Williams B. L., Hoagland T. A., Ditullio P. A., Ebert K. M., Fodor W. L. Expression of the human alpha1,2-fucosyltransferase in transgenic pigs modifies the cell surface carbohydrate phenotype and confers resistance to human serum-mediated cytolysis. FASEB J. 1999 Oct;13(13):1762–1773. doi: 10.1096/fasebj.13.13.1762. [DOI] [PubMed] [Google Scholar]
  11. Cozzi E., White D. J. The generation of transgenic pigs as potential organ donors for humans. Nat Med. 1995 Sep;1(9):964–966. doi: 10.1038/nm0995-964. [DOI] [PubMed] [Google Scholar]
  12. Davitz M. A., Low M. G., Nussenzweig V. Release of decay-accelerating factor (DAF) from the cell membrane by phosphatidylinositol-specific phospholipase C (PIPLC). Selective modification of a complement regulatory protein. J Exp Med. 1986 May 1;163(5):1150–1161. doi: 10.1084/jem.163.5.1150. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Dickson D. Pig heart transplant 'breakthrough' stirs debate over timing of trials. Nature. 1995 Sep 21;377(6546):185–186. doi: 10.1038/377185a0. [DOI] [PubMed] [Google Scholar]
  14. Dorling A., Lechler R. I. Prospects for xenografting. Curr Opin Immunol. 1994 Oct;6(5):765–769. doi: 10.1016/0952-7915(94)90082-5. [DOI] [PubMed] [Google Scholar]
  15. Fabre J. W. Nudging xenotransplantation towards humans. Nat Med. 1995 May;1(5):403–404. doi: 10.1038/nm0595-403. [DOI] [PubMed] [Google Scholar]
  16. Fiane A. E., Mollnes T. E., Degré M. Pig endogenous retrovirus--a threat to clinical xenotransplantation? APMIS. 2000 Apr;108(4):241–250. doi: 10.1034/j.1600-0463.2000.d01-51.x. [DOI] [PubMed] [Google Scholar]
  17. Gridelli B., Remuzzi G. Strategies for making more organs available for transplantation. N Engl J Med. 2000 Aug 10;343(6):404–410. doi: 10.1056/NEJM200008103430606. [DOI] [PubMed] [Google Scholar]
  18. Guidance on xenotransplantation sought. Nat Med. 1997 Sep;3(9):935–935. doi: 10.1038/nm0997-935. [DOI] [PubMed] [Google Scholar]
  19. Guidance on xenotransplantation sought. Nat Med. 1997 Sep;3(9):935–935. doi: 10.1038/nm0997-935. [DOI] [PubMed] [Google Scholar]
  20. Günzburg W. H., Salmons B. Xenotransplantation: is the risk of viral infection as great as we thought? Mol Med Today. 2000 May;6(5):199–208. doi: 10.1016/s1357-4310(00)01708-1. [DOI] [PubMed] [Google Scholar]
  21. Hahn B. H., Shaw G. M., De Cock K. M., Sharp P. M. AIDS as a zoonosis: scientific and public health implications. Science. 2000 Jan 28;287(5453):607–614. doi: 10.1126/science.287.5453.607. [DOI] [PubMed] [Google Scholar]
  22. Hillmen P., Lewis S. M., Bessler M., Luzzatto L., Dacie J. V. Natural history of paroxysmal nocturnal hemoglobinuria. N Engl J Med. 1995 Nov 9;333(19):1253–1258. doi: 10.1056/NEJM199511093331904. [DOI] [PubMed] [Google Scholar]
  23. Hourcade D., Garcia A. D., Post T. W., Taillon-Miller P., Holers V. M., Wagner L. M., Bora N. S., Atkinson J. P. Analysis of the human regulators of complement activation (RCA) gene cluster with yeast artificial chromosomes (YACs). Genomics. 1992 Feb;12(2):289–300. doi: 10.1016/0888-7543(92)90376-4. [DOI] [PubMed] [Google Scholar]
  24. Hudson R. P. Immortal quackery. Med Herit. 1985 Jan-Feb;1(1):58–67. [PubMed] [Google Scholar]
  25. Kaufman C. L., Gaines B. A., Ildstad S. T. Xenotransplantation. Annu Rev Immunol. 1995;13:339–367. doi: 10.1146/annurev.iy.13.040195.002011. [DOI] [PubMed] [Google Scholar]
  26. Kroshus T. J., Bolman R. M., 3rd, Dalmasso A. P. Potential of anticomplement therapy in clinical transplantation. BioDrugs. 1998 Aug;10(2):111–121. doi: 10.2165/00063030-199810020-00003. [DOI] [PubMed] [Google Scholar]
  27. Lin S. S., Weidner B. C., Byrne G. W., Diamond L. E., Lawson J. H., Hoopes C. W., Daniels L. J., Daggett C. W., Parker W., Harland R. C. The role of antibodies in acute vascular rejection of pig-to-baboon cardiac transplants. J Clin Invest. 1998 Apr 15;101(8):1745–1756. doi: 10.1172/JCI2134. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Liszewski M. K., Farries T. C., Lublin D. M., Rooney I. A., Atkinson J. P. Control of the complement system. Adv Immunol. 1996;61:201–283. doi: 10.1016/s0065-2776(08)60868-8. [DOI] [PubMed] [Google Scholar]
  29. Logan J. S. Prospects for xenotransplantation. Curr Opin Immunol. 2000 Oct;12(5):563–568. doi: 10.1016/s0952-7915(00)00139-4. [DOI] [PubMed] [Google Scholar]
  30. Logan J. S., Sharma A. Potential use of genetically modified pigs as organ donors for transplantation into humans. Clin Exp Pharmacol Physiol. 1999 Dec;26(12):1020–1025. doi: 10.1046/j.1440-1681.1999.03185.x. [DOI] [PubMed] [Google Scholar]
  31. Loss M., Vangerow B., Schmidtko J., Kunz R., Jalali A., Arends H., Przemeck M., Rückholt H., Leuwer M., Kaup F. J. Acute vascular rejection is associated with systemic complement activation in a pig-to-primate kidney xenograft model. Xenotransplantation. 2000 Aug;7(3):186–196. doi: 10.1034/j.1399-3089.2000.00059.x. [DOI] [PubMed] [Google Scholar]
  32. Lu C. Y., Khair-el-Din T. A., Dawidson I. A., Butler T. M., Brasky K. M., Vazquez M. A., Sicher S. C. Xenotransplantation. FASEB J. 1994 Nov;8(14):1122–1130. doi: 10.1096/fasebj.8.14.7958617. [DOI] [PubMed] [Google Scholar]
  33. Marwick C. British, American reports on xenotransplantation. JAMA. 1996 Aug 28;276(8):589–590. [PubMed] [Google Scholar]
  34. McCurry K. R., Kooyman D. L., Alvarado C. G., Cotterell A. H., Martin M. J., Logan J. S., Platt J. L. Human complement regulatory proteins protect swine-to-primate cardiac xenografts from humoral injury. Nat Med. 1995 May;1(5):423–427. doi: 10.1038/nm0595-423. [DOI] [PubMed] [Google Scholar]
  35. Michaels M. G., Simmons R. L. Xenotransplant-associated zoonoses. Strategies for prevention. Transplantation. 1994 Jan;57(1):1–7. doi: 10.1097/00007890-199401000-00001. [DOI] [PubMed] [Google Scholar]
  36. Miyata T., Takeda J., Iida Y., Yamada N., Inoue N., Takahashi M., Maeda K., Kitani T., Kinoshita T. The cloning of PIG-A, a component in the early step of GPI-anchor biosynthesis. Science. 1993 Feb 26;259(5099):1318–1320. doi: 10.1126/science.7680492. [DOI] [PubMed] [Google Scholar]
  37. Morris P. J. Xenotransplantation. Br Med Bull. 1999;55(2):446–459. doi: 10.1258/0007142991902367. [DOI] [PubMed] [Google Scholar]
  38. Murphy F. A. The public health risk of animal organ and tissue transplantation into humans. Science. 1996 Aug 9;273(5276):746–747. doi: 10.1126/science.273.5276.746. [DOI] [PubMed] [Google Scholar]
  39. Novak K. US FDA to issue new rules on xenotransplantation. Nat Med. 1998 Aug;4(8):876–876. doi: 10.1038/nm0898-876a. [DOI] [PubMed] [Google Scholar]
  40. Nowak R. Xenotransplants set to resume. Science. 1994 Nov 18;266(5188):1148–1151. doi: 10.1126/science.7973690. [DOI] [PubMed] [Google Scholar]
  41. Oglesby T. J., Allen C. J., Liszewski M. K., White D. J., Atkinson J. P. Membrane cofactor protein (CD46) protects cells from complement-mediated attack by an intrinsic mechanism. J Exp Med. 1992 Jun 1;175(6):1547–1551. doi: 10.1084/jem.175.6.1547. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Parker W., Bruno D., Holzknecht Z. E., Platt J. L. Characterization and affinity isolation of xenoreactive human natural antibodies. J Immunol. 1994 Oct 15;153(8):3791–3803. [PubMed] [Google Scholar]
  43. Parker W., Bruno D., Platt J. L. Xenoreactive natural antibodies in the world of natural antibodies: typical or unique? Transpl Immunol. 1995 Sep;3(3):181–191. doi: 10.1016/0966-3274(95)80024-7. [DOI] [PubMed] [Google Scholar]
  44. Patience C., Takeuchi Y., Weiss R. A. Infection of human cells by an endogenous retrovirus of pigs. Nat Med. 1997 Mar;3(3):282–286. doi: 10.1038/nm0397-282. [DOI] [PubMed] [Google Scholar]
  45. Platt J. L., Nagayasu T. Current status of xenotransplantation. Clin Exp Pharmacol Physiol. 1999 Dec;26(12):1026–1032. doi: 10.1046/j.1440-1681.1999.03186.x. [DOI] [PubMed] [Google Scholar]
  46. Rosse W. F. Evolution of clinical understanding: paroxysmal nocturnal hemoglobinuria as a paradigm. Am J Hematol. 1993 Jan;42(1):122–126. doi: 10.1002/ajh.2830420124. [DOI] [PubMed] [Google Scholar]
  47. Rosse W. F. Paroxysmal nocturnal hemoglobinuria as a molecular disease. Medicine (Baltimore) 1997 Mar;76(2):63–93. doi: 10.1097/00005792-199703000-00001. [DOI] [PubMed] [Google Scholar]
  48. Rosse W. F. Phosphatidylinositol-linked proteins and paroxysmal nocturnal hemoglobinuria. Blood. 1990 Apr 15;75(8):1595–1601. [PubMed] [Google Scholar]
  49. Roush W. New ways to avoid organ rejection buoy hopes. Science. 1995 Oct 13;270(5234):234–235. doi: 10.1126/science.270.5234.234. [DOI] [PubMed] [Google Scholar]
  50. Ryan U. S. Complement inhibitory therapeutics and xenotransplantation. Nat Med. 1995 Sep;1(9):967–968. doi: 10.1038/nm0995-967. [DOI] [PubMed] [Google Scholar]
  51. Saadi S., Platt J. L. Role of complement in xenotransplantation. Clin Exp Pharmacol Physiol. 1999 Dec;26(12):1016–1019. doi: 10.1046/j.1440-1681.1999.03184.x. [DOI] [PubMed] [Google Scholar]
  52. Sachs D. H. Mixed chimerism as an approach to transplantation tolerance. Clin Immunol. 2000 Apr;95(1 Pt 2):S63–S68. doi: 10.1006/clim.1999.4814. [DOI] [PubMed] [Google Scholar]
  53. Sachs D. H. The pig as a potential xenograft donor. Vet Immunol Immunopathol. 1994 Oct;43(1-3):185–191. doi: 10.1016/0165-2427(94)90135-x. [DOI] [PubMed] [Google Scholar]
  54. Sandrin M. S., McKenzie I. F. Recent advances in xenotransplantation. Curr Opin Immunol. 1999 Oct;11(5):527–531. doi: 10.1016/s0952-7915(99)00011-4. [DOI] [PubMed] [Google Scholar]
  55. Socié G., Mary J. Y., de Gramont A., Rio B., Leporrier M., Rose C., Heudier P., Rochant H., Cahn J. Y., Gluckman E. Paroxysmal nocturnal haemoglobinuria: long-term follow-up and prognostic factors. French Society of Haematology. Lancet. 1996 Aug 31;348(9027):573–577. doi: 10.1016/s0140-6736(95)12360-1. [DOI] [PubMed] [Google Scholar]
  56. Stafford H. A., Tykocinski M. L., Lublin D. M., Holers V. M., Rosse W. F., Atkinson J. P., Medof M. E. Normal polymorphic variations and transcription of the decay accelerating factor gene in paroxysmal nocturnal hemoglobinuria cells. Proc Natl Acad Sci U S A. 1988 Feb;85(3):880–884. doi: 10.1073/pnas.85.3.880. [DOI] [PMC free article] [PubMed] [Google Scholar]
  57. Takeda J., Miyata T., Kawagoe K., Iida Y., Endo Y., Fujita T., Takahashi M., Kitani T., Kinoshita T. Deficiency of the GPI anchor caused by a somatic mutation of the PIG-A gene in paroxysmal nocturnal hemoglobinuria. Cell. 1993 May 21;73(4):703–711. doi: 10.1016/0092-8674(93)90250-t. [DOI] [PubMed] [Google Scholar]
  58. Travis John. The xeno-solution: perils and promise of transplanting animal organs into people. Sci News. 1995 Nov 4;148(19):298–301. [PubMed] [Google Scholar]
  59. US guidelines on xenotransplantation. Nat Med. 1999 May;5(5):465–465. doi: 10.1038/8325. [DOI] [PubMed] [Google Scholar]
  60. Weiss R. A. Xenografts and retroviruses. Science. 1999 Aug 20;285(5431):1221–1222. doi: 10.1126/science.285.5431.1221. [DOI] [PubMed] [Google Scholar]
  61. White D. J., Oglesby T., Liszewski M. K., Tedja I., Hourcade D., Wang M. W., Wright L., Wallwork J., Atkinson J. P. Expression of human decay accelerating factor or membrane cofactor protein genes on mouse cells inhibits lysis by human complement. Transplant Proc. 1992 Apr;24(2):474–476. [PubMed] [Google Scholar]
  62. Yang Y. G., deGoma E., Ohdan H., Bracy J. L., Xu Y., Iacomini J., Thall A. D., Sykes M. Tolerization of anti-Galalpha1-3Gal natural antibody-forming B cells by induction of mixed chimerism. J Exp Med. 1998 Apr 20;187(8):1335–1342. doi: 10.1084/jem.187.8.1335. [DOI] [PMC free article] [PubMed] [Google Scholar]
  63. Yannoutsos N., Langford G. A., Cozzi E., Lancaster R., Elsome K., Chen P., White D. J. Production of pigs transgenic for human regulators of complement activation. Transplant Proc. 1995 Feb;27(1):324–325. [PubMed] [Google Scholar]
  64. van Denderen B. J., Salvaris E., Romanella M., Aminian A., Katerelos M., Tange M. J., Pearse M. J., d'Apice A. J. Combination of decay-accelerating factor expression and alpha1,3-galactosyltransferase knockout affords added protection from human complement-mediated injury. Transplantation. 1997 Sep 27;64(6):882–888. doi: 10.1097/00007890-199709270-00016. [DOI] [PubMed] [Google Scholar]

Articles from Transactions of the American Clinical and Climatological Association are provided here courtesy of American Clinical and Climatological Association

RESOURCES